Information  X 
Enter a valid email address

Qiagen N.V. (0H1Z)

  Print      Mail a friend       Annual reports

Monday 14 December, 2009

Qiagen N.V.

QIAGEN Added to NASDAQ-100 Index

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 

VENLO, The  Netherlands, December  14, 2009  - QIAGEN  N.V.  (NASDAQ:
QGEN; Frankfurt, Prime Standard: QIA) today announced that its common
shares will be included in the  NASDAQ-100 Index effective as of  the
start of trading on December 21, 2009. The NASDAQ-100 Index comprises
the top  100  non-financial securities  listed  on The  NASDAQ  Stock
Market based on market capitalization. Launched in January 1985,  the
NASDAQ-100 Index includes companies across major industry groups.

"The addition of our securities to the NASDAQ-100 Index reflects  our
strong  growth,   consistent   performance  and   significant   value
creation", said Peer M. Schatz, CEO of QIAGEN. "We are honoured to be
added to this elite  set of companies".  QIAGEN's common shares  have
been trading on The NASDAQ  Stock Market since the Company's  initial
public offering on June 28, 1996.

QIAGEN   N.V.,    a    Netherlands   holding    company,    is    the
leading global provider of  sample  and  assay  technologies.  Sample
technologies are used to  isolate and process  DNA, RNA and  proteins
from biological samples such  as blood or tissue. Assay  technologies
are used  to make  such isolated  bio-molecules visible.  QIAGEN  has
developed and markets more than 500 sample and assay products as well
as automated solutions for such consumables. The company provides its
products to molecular diagnostics laboratories, academic researchers,
pharmaceutical   and    biotechnology    companies,    and    applied
testing customers for  purposes such  as forensics,  animal  or  food
testing   and   pharmaceutical   process   control. QIAGEN's    assay
technologies  include  one  of  the  broadest  panels  of   molecular
diagnostic  tests  available  worldwide.  This  panel  includes   the
digeneHPV Test, which is regarded as a "gold standard" in testing for
high-risk types of human papillomavirus  (HPV), the primary cause  of
cervical cancer, as well as a broad suite of solutions for infectious
disease testing and companion  diagnostics. QIAGEN employs more  than
3,400 people  in over  30  locations worldwide.  Further  information
about QIAGEN can be found at

Statements contained in  this release that  are not historical  facts
are  forward-looking  statements,  including  statements  about   our
products, markets, strategy  and operating  results. Such  statements
are  based   on  current   expectations   that  involve   risks   and
uncertainties including, but not  limited to, those associated  with:
management of growth and international operations (including currency
fluctuations and logistics),  variability of  our operating  results,
commercial development  of our  markets (including  applied  testing,
clinical  and  academic  research,  proteomics,  women's   health/HPV
testing, molecular diagnostics, personalized healthcare and companion
diagnostics),  our  relationships   with  customers,  suppliers   and
strategic partners, competition, changes in technology,  fluctuations
in  demand,  regulatory  requirements,  identifying,  developing  and
producing integrated  products differentiated  from our  competitors'
products, market  acceptance  of  our products,  and  integration  of
acquired technologies and businesses. For further information,  refer
to our filings with  the SEC, including our  latest Annual Report  on
Form 20-F.  Information in  this release  is as  of the  date of  the
release, and we undertake no  duty to update this information  unless
required by law.
                                # # #


Investor Relations:                  Public Relations:
Dr. Solveigh Mähler                  Dr. Thomas Theuringer
Director Investor Relations          Associate    Director     Public
QIAGEN N.V.                          Relations
+49 2103 29 11710                    QIAGEN GmbH
e-mail:                              +49-2103-29-11826
[email protected]          e-mail:
                                     [email protected]
Albert F. Fleury
Investor Relations North America
+1 301 944 7028
e-mail: [email protected]

--- End of Message ---

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626; ISIN: 
NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, 
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in 
Bayerische Börse München, 
Freiverkehr in Börse Stuttgart;


a d v e r t i s e m e n t